株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

液体生検 (リキッドバイオプシー) の世界市場における成長機会

Growth Opportunities in the Global Liquid Biopsy Market, 2018

発行 Frost & Sullivan 商品コード 731212
出版日 ページ情報 英文 81 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.11円で換算しております。
液体生検 (リキッドバイオプシー) の世界市場における成長機会 Growth Opportunities in the Global Liquid Biopsy Market, 2018
出版日: 2018年10月05日 ページ情報: 英文 81 Pages
概要

液体生検は、従来の組織に基づく黄金律を上回る長所により、臨床現場で緩やかに浸透しています。液体生検は投資家にとって興味深いビジネスチャンスとなっています。

当レポートでは、世界の液体生検市場について調査し、市場の現状と競合動向、地域別分析、主要企業の成長戦略などをまとめています。

第1章 エグゼクティブダッシュボード

第2章 市場概要

  • 液体生検とは
  • 液体生検技術とバイオマーカーの概要
  • 成長の機会はどこにあるか
  • 腫瘍に特化した機会の探求
  • 生検の概要
  • 主なステークホルダー
  • 液体治験
  • 市況:医薬品業界への透視
  • 市場促進因子
  • 市場阻害因子
  • 市販化された検査
  • 液体生検検査がNCDに及ぼす影響
  • 特筆すべき市場活動
  • 市況:投資

第3章 競合環境

  • 全体的競合環境:企業のタイプ
  • 競合環境概要:サービスプロバイダー
  • 3つの動向とベンダー戦略
  • 液体生検の注目分野
  • 競合分析概要
  • 投資と技術
  • バイオマーカーと技術選択分析
  • 競合マトリクス:製品タイプ

第4章 地域別分析

  • 世界の液体生検導入予測
  • 米国
  • 欧州/英国
  • 中国
  • インド

第5章 成長戦略

  • 成長の機会
  • 治療への反応を予測するツール
  • 予後と癌の早期発見
  • 一般的癌以外の分野
  • 技術進歩
  • 液体生検市場参入企業の戦略
  • 推奨される成長戦略
  • 臨床バリデーションの重要性、臨床有用性、償還経路
  • GRAIL:強固な治験戦略とAI/MLを用いた技術優位性
  • Guardant Health:再発モニタリングにおける地位を確立
  • Freenome:マシンラーニングテクノロジーに早くから注目した企業
  • biocept
  • Natera:NIPT専門性を確立
  • 注目企業
  • 償還経路/補償

第6章 最後に

第7章 付録

目次
Product Code: K294-55

Companies are Vying for a Higher Market Position in the Early Cancer Screening Market

Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such as high cost of next-generation sequencing (NGS), reimbursement scenario and the establishment of clinical utility of mutation and clinical evidence.

Liquid biopsy remains an interesting business opportunity for several investors and the quest for the most successful company continues. With GRAIL announcing over $1.3 billion in financing, the modality has also garnered interest from several pharma companies vying to capture their share of the market by co-developing drugs and diagnostic products. CTCs and ctDNAs have extended applications across oncology, NIPT (non-invasive prenatal testing), transplant diagnostics and infectious diseases. This report provides a strategic insight into liquid biopsy test makers relating to the challenges they will encounter and lists some of the winning strategies to gain reimbursement and market access. It also highlights growth opportunities where companies can gain the first-mover advantage, and provides a guidance for investment bankers on the most successful and unique disruptive technology.

It is important to identify winning strategies in order to be successful. Given the tricky nature of this market, establishing clinical utility and clinical evidence and getting the test into guidelines are some of the key pathways for success. This report discusses regional challenges, regulatory barriers in the UK, China and the US. Key drivers would include the following: Identifying the area of unmet need; aiming for incorporating the test within guidelines and screening programs; overcoming regulatory and reimbursement barriers; and innovating to draw maximum capital from investors.

Broadly three types of companies form the competitive landscape in this market - liquid biopsy kit providers, liquid biopsy instrument providers. Most activity is sensed within “liquid biopsy as a service model”.

Currently, there are no clear guidelines that provide a definitive regulatory/ reimbursement roadmap in emerging countries such as India where the concept is still in its nascent stages.

Top market trends include:

  • Increasing interest from pharma companies forging partnerships with diagnostic test developers to advance their drug discovery and development activities.
  • Companies are leaning towards biomarkers that are listed in the NCCN guidelines as a low-risk approach and which offer more guaranteed reimbursement.
  • Biomarker tests are focusing on multi-gene or multi-cancer testing rather than a single gene approach.
  • Companies are pushing the boundaries beyond oncology testing.

Table of Contents

1. EXECUTIVE DASHBOARD

  • Purpose of this Experiential Study
  • 5 Step Process to Transformational Growth
  • Scope and Segmentation
  • Market Highlights
  • Strategic Imperatives for Suppliers and Laboratories
  • Growth Themes for the Liquid Biopsy Market
  • Key Questions this Study will Answer
  • Top 3 Predictions

2. MARKET OVERVIEW

  • What is Liquid Biopsy?
  • Overview of Liquid Biopsy Techniques and Biomarkers
  • Liquid Biopsy-Where are the Growth Opportunities?
  • Tapping into Oncology-specific Opportunities
  • Deeper Look Into Biopsies
  • Key Stakeholders (Full Adoption of Liquid Biopsy)
  • Clinical Trials in Liquid Biopsy
  • Market Landscape-Pharmaceutical Investments
  • Market Drivers
  • Market Restraints
  • Commercialized Tests (US)
  • Impact of NCD on Liquid Biopsy Testing
  • Notable Market Activities
  • Notable Market Activities (continued)
  • Notable Market Activities (continued)
  • Market Landscape-Investments

3. COMPETITOR LANDSCAPE

  • Overall Competitive Landscape-Types of Companies
  • Overview of Competitive Landscape-Service Providers
  • Top 3 Trends and Vendor Strategies
  • Key Focus Areas of Liquid Biopsy Companies
  • Liquid Biopsy Service Provider-Competitor Analysis Snapshot
  • Liquid Biopsy Service Provider-Competitor Analysis Snapshot (continued)
  • Investments and Technology-By Company
  • Investment and Technology-By Company (continued)
  • Investment and Technology-By Company (continued)
  • Investment and Technology-By Company (continued)
  • Investment and Technology-By Company (continued)
  • Investments-By Technology
  • Biomarker and Technology Choice Analysis
  • Competitor Matrix-Product Type
  • Competitor Matrix-Product Type (continued)

4. REGIONAL ANALYSIS

  • Predictions on Adoption of Liquid Biopsy Across Geographies
  • Analysis-US
  • Analysis-Europe/UK
  • Analysis-China
  • Analysis-India

5. GROWTH STRATEGY

  • Growth Opportunities
  • Growth Opportunity 1-Tool to Predict Response to Therapy
  • Growth Opportunity 2-Prognosis and Early Detection for Cancer
  • Growth Opportunity 3-Moving Beyond Routine Cancers
  • Growth Opportunity 4-Technology Advancements
  • 2018 Liquid Biopsy Market Participant Strategies
  • 2018 Liquid Biopsy Market Participant Strategies (continued)
  • 2018 Liquid Biopsy Market Participant Strategies (continued)
  • 2018 Liquid Biopsy Market Participant Strategies (continued)
  • Winning Strategies-Recommended Growth Strategies
  • Winning Strategies-Recommended Growth Strategies (continued)
  • Importance of Clinical Validation and Clinical Utility and Path to Reimbursement
  • GRAIL-Strong Clinical Trial Strategy and Technology Superiority Using AI/ML
  • Guardant Health-Established Presence in Recurrence Monitoring
  • Freenome-Early-stage Company Focusing on Machine Learning Technology
  • Biocept
  • Natera-Building on the NIPT Expertise
  • Companies to Action (C2A Summary)
  • Path to Reimbursement/Coverage

6. THE LAST WORD

  • Key Conclusions and Future Outlook
  • Acronyms
  • Legal Disclaimer

7. APPENDIX (CAPITAL PRICING AND INSTALLED BASE)

  • List of Companies Mentioned in the Report
  • List of Exhibits